Black Diamond Therapeutics, Inc. BDTX
We take great care to ensure that the data presented and summarized in this overview for Black Diamond Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BDTX
View all-
Bellevue Group Ag Kuesnacht, V88.52MShares$41.5 Million0.68% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.73MShares$32.8 Million0.02% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$21.7 Million1.58% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.91MShares$9.28 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.6MShares$7.81 Million0.99% of portfolio
-
Black Rock Inc. New York, NY1.38MShares$6.72 Million0.0% of portfolio
-
Artal Group S.A. Luxembourg, N41.05MShares$5.1 Million0.29% of portfolio
-
Laurion Capital Management LP New York, NY878KShares$4.28 Million0.04% of portfolio
-
Chi Advisors LLC New York, NY720KShares$3.51 Million1.02% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO717KShares$3.49 Million0.08% of portfolio
Latest Institutional Activity in BDTX
Top Purchases
Top Sells
About BDTX
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at BDTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2024
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
3,166
+5.77%
|
$12,664
$4.54 P/Share
|
|
Mar 15
2024
|
Wendy L Dixon |
BUY
Grant, award, or other acquisition
|
Direct |
3,253
+7.88%
|
$13,012
$4.54 P/Share
|
|
Dec 15
2023
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
4,455
+8.41%
|
$8,910
$2.73 P/Share
|
|
Dec 15
2023
|
Wendy L Dixon |
BUY
Grant, award, or other acquisition
|
Direct |
4,043
+10.41%
|
$8,086
$2.73 P/Share
|
|
Oct 17
2023
|
Growth N V Biotech |
BUY
Open market or private purchase
|
Direct |
400,000
+4.49%
|
$800,000
$2.34 P/Share
|
|
Sep 15
2023
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
3,299
+6.96%
|
$9,897
$3.6 P/Share
|
|
Sep 15
2023
|
Wendy L Dixon |
BUY
Grant, award, or other acquisition
|
Direct |
2,986
+8.85%
|
$8,958
$3.6 P/Share
|
|
Sep 15
2023
|
Mark A. Velleca PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
5,208
+10.07%
|
$15,624
$3.6 P/Share
|
|
Jul 05
2023
|
Ra Capital Management, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
935,850
+22.55%
|
$4,679,250
$5.0 P/Share
|
|
Jul 05
2023
|
Ali Behbahani |
BUY
Open market or private purchase
|
Indirect |
1,000,000
+18.35%
|
$5,000,000
$5.0 P/Share
|
|
Jun 30
2023
|
Growth N V Biotech |
BUY
Open market or private purchase
|
Direct |
1,000,000
+10.97%
|
$5,000,000
$5.0 P/Share
|
|
Jun 27
2023
|
Growth N V Biotech |
BUY
Open market or private purchase
|
Direct |
1,740,000
+19.64%
|
$8,700,000
$5.49 P/Share
|
|
Jun 27
2023
|
David M. Epstein |
SELL
Open market or private sale
|
Direct |
25,000
-3.59%
|
$150,000
$6.7 P/Share
|
|
Jun 16
2023
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
5,655
+12.18%
|
$11,310
$2.1 P/Share
|
|
Jun 16
2023
|
Mark A. Velleca PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,929
+17.77%
|
$17,858
$2.1 P/Share
|
|
Jun 16
2023
|
Wendy L Dixon |
BUY
Grant, award, or other acquisition
|
Direct |
5,119
+15.56%
|
$10,238
$2.1 P/Share
|
|
Mar 16
2023
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
7,111
+16.84%
|
$7,111
$1.67 P/Share
|
|
Mar 16
2023
|
Mark A. Velleca PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
11,228
+25.74%
|
$11,228
$1.67 P/Share
|
|
Mar 16
2023
|
Wendy L Dixon |
BUY
Grant, award, or other acquisition
|
Direct |
6,437
+22.13%
|
$6,437
$1.67 P/Share
|
|
Feb 13
2023
|
Erika Jones |
BUY
Grant, award, or other acquisition
|
Direct |
5,075
+33.33%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 5.08M shares |
|---|---|
| Grant, award, or other acquisition | 46.1K shares |
| Open market or private sale | 25K shares |
|---|